Identifying EGFR status is one of the first steps in advanced-stage NSCLC management, as molecular targeted therapy is the standard of care in first-line treatment for patients carrying identified driver mutations in this gene [20,21,22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.